These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10993230)

  • 1. Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere.
    Mimoto T; Hattori N; Takaku H; Kisanuki S; Fukazawa T; Terashima K; Kato R; Nojima S; Misawa S; Ueno T; Imai J; Enomoto H; Tanaka S; Sakikawa H; Shintani M; Hayashi H; Kiso Y
    Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1310-26. PubMed ID: 10993230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere.
    Kiso Y
    Biopolymers; 1996; 40(2):235-44. PubMed ID: 8785365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
    Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
    J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine.
    Mimoto T; Imai J; Kisanuki S; Enomoto H; Hattori N; Akaji K; Kiso Y
    Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2251-3. PubMed ID: 1423795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.
    Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K
    Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.
    Kageyama S; Mimoto T; Murakawa Y; Nomizu M; Ford H; Shirasaka T; Gulnik S; Erickson J; Takada K; Hayashi H
    Antimicrob Agents Chemother; 1993 Apr; 37(4):810-7. PubMed ID: 8494379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure.
    Mimoto T; Terashima K; Nojima S; Takaku H; Nakayama M; Shintani M; Yamaoka T; Hayashi H
    Bioorg Med Chem; 2004 Jan; 12(1):281-93. PubMed ID: 14697794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
    Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
    Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic.
    Mimoto T; Imai J; Tanaka S; Hattori N; Kisanuki S; Akaji K; Kiso Y
    Chem Pharm Bull (Tokyo); 1991 Nov; 39(11):3088-90. PubMed ID: 1799953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.
    Baldwin ET; Bhat TN; Gulnik S; Liu B; Topol IA; Kiso Y; Mimoto T; Mitsuya H; Erickson JW
    Structure; 1995 Jun; 3(6):581-90. PubMed ID: 8590019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic.
    Mimoto T; Imai J; Tanaka S; Hattori N; Takahashi O; Kisanuki S; Nagano Y; Shintani M; Hayashi H; Sakikawa H
    Chem Pharm Bull (Tokyo); 1991 Sep; 39(9):2465-7. PubMed ID: 1804562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins.
    Kageyama S; Anderson BD; Hoesterey BL; Hayashi H; Kiso Y; Flora KP; Mitsuya H
    Antimicrob Agents Chemother; 1994 May; 38(5):1107-11. PubMed ID: 8067746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI.
    Chokekijchai S; Shirasaka T; Weinstein JN; Mitsuya H
    Antiviral Res; 1995 Sep; 28(1):25-38. PubMed ID: 8585758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solution conformations of KNI-272, a tripeptide HIV protease inhibitor designed on the basis of substrate transition state: determined by NMR spectroscopy and simulated annealing calculations.
    Ohno Y; Kiso Y; Kobayashi Y
    Bioorg Med Chem; 1996 Sep; 4(9):1565-72. PubMed ID: 8894113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of pseudo-symmetric HIV protease inhibitors containing a novel hydroxymethylcarbonyl (HMC)-hydrazide isostere.
    Hidaka K; Kimura T; Hayashi Y; McDaniel KF; Dekhtyar T; Colletti L; Kiso Y
    Bioorg Med Chem Lett; 2003 Jan; 13(1):93-6. PubMed ID: 12467624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rigid backbone moiety of KNI-272, a highly selective HIV protease inhibitor: methanol, acetone and dimethylsulfoxide solvated forms of 3-[3-benzyl-2-hydroxy-9-(isoquinolin-5-yloxy)-6-methylsulfanylmethyl-5,8-dioxo-4,7-diazanonanoyl]-N-tert-butyl-1,3-thiazolidine-4-carboxamide.
    Doi M; Kimura T; Ishida T; Kiso Y
    Acta Crystallogr B; 2004 Aug; 60(Pt 4):433-7. PubMed ID: 15258401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
    Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
    Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.
    Le VD; Mak CC; Lin YC; Elder JH; Wong CH
    Bioorg Med Chem; 2001 May; 9(5):1185-95. PubMed ID: 11377177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of the protease from human immunodeficiency virus: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity.
    Thaisrivongs S; Tomasselli AG; Moon JB; Hui J; McQuade TJ; Turner SR; Strohbach JW; Howe WJ; Tarpley WG; Heinrikson RL
    J Med Chem; 1991 Aug; 34(8):2344-56. PubMed ID: 1875334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of HIV protease inhibitors containing allophenylnorstatine as a transition-state mimic.
    Kiso Y
    Adv Exp Med Biol; 1995; 362():413-23. PubMed ID: 8540352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.